^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VMD-928

    i
    Other names: VMD-928
    Associations
    News

    Trials

    Company:
    Vm Oncology
    Drug class:
    TrkA receptor antagonist
    Related drugs:
    Associations
    News

    Trials

    Apply
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228)
    Phase 1
    VM Oncology, LLC
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/08/2018
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    NTRK1
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928